Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …

Aim: This study aimed to analyze whether or not the efficacy and safety of erlotinib are
influenced by differences among treatment lines and initiation timing in advanced non-small …

Introduction: This phase 2 study was conducted to determine the efficacy and safety of
erlotinib alone and with bortezomib in patients with non-small cell lung cancer (NSCLC) …

Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …

Introduction: Epidermal growth factor receptor-tyrosine kinase inhibitors are used as
effective first-line and salvage therapy in the treatment of advanced non-small cell lung …

Erlotinib is a relatively well-tolerated treatment option for patients with advanced non-small-
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …

Background and objective: Erlotinib is one of the standard second/third line treatments for
patients with advanced non‐small cell lung cancer (NSCLC). This study investigated the …

Erlotinib (Tarceva™, OSI-774; Pfizer, Inc.) is an orally-active, targeted inhibitor of the
epidermal growth factor receptor (EGFR/HER1), which is part of a key regulatory pathway in …

Gefitinib, an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), has been
approved in Japan for the treatment of patients with advanced non-small-cell lung cancer …

Background: Erlotinib is approved as treatment for metastatic non-small-cell lung cancer
(NSCLC), following failure of initial therapy. Studies to define patients that derive maximal …